ASSERTION FOR MONTELUKAST IN THE COVID-19 PANDEMICS?
ANDRA IULIA SUCEVEANU 1#, LAURA MAZILU 1, ADRIAN PAUL SUCEVEANU 1, IRINEL PAREPA 1, ION-BOGDAN DUMITRESCU 2*, CRISTINA MANUELA DRĂGOI 2, ALINA CRENGUȚA NICOLAE 2, FLORIN BOTEA 3, FELIX VOINEA 1#, GEORGE TRAIAN ALEXANDRU BURCEA-DRAGOMIROIU 2
1.Faculty of Medicine, “Ovidius” University of Constanța, Romania
2.“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
3.Liver Transplant and General Surgery Centre, Fundeni Intitute, 022338, Bucharest, Romania
Download Full Article PDF
The ongoing pandemic coronavirus disease (COVID-19) is an infection caused by a newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). The treatment of COVID-19 patients represents a continuous challenge, no vaccine or specific antiviral therapy is yet available. International guidelines recommend the medical management based only on the first line physicians' short expertise, off-label approaches being admitted worldwide to limit and to decrease the infection devastating impacts on humans’ health. A marketed drug used for asthma, known generically as montelukast, gives light in the attempt of clinicians during their efforts to combat SARS-CoV2 spreading. Even not yet approved by FDA or EMA for COVID-19 infection indication, many clinicians are raising-up the idea of turning attention and attempts to off-label medical options like montelukast use, considering this drug an alternative or additive therapeutic approach for prevention and treating pulmonary distress.